Author
Curam, Centre for Research in Medical Devices, National University of Ireland Galway, NUIGalway, Biosciences Research Building, 118 Corrib Village, Newcastle, Galway, Ireland
Abstract
Keywords
Open Access Policy: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/
1.Clauw DJ, Schmidt M, Radulovic D, Singer A, Katz P, Bresette J. The relationship between fibromyalgia and interstitial cystitis. J Psychiatr Res. 1997;31(1):125-31. [PubMed: 9201654]. https://doi.org/10.1016/S0022-3956(96)00051-9 PMid:9201654 |
||||
2. Oravisto KJ. Epidemiology of interstitial cystitis. Ann Chir Gynaecol Fenn. 1975;64(2):75-7. [PubMed: 1137336]. | ||||
3. Lifford KL, Curhan GC. Prevalence of painful bladder syndrome in older women. Urology. 2009;73(3):494-8. [PubMed: 19118882]. https://doi.org/10.1016/j.urology.2008.01.053 PMid:19118882 |
||||
4. Koziol JA. Epidemiology of interstitial cystitis. Urol Clin North Am. 1994;21(1):7-20. [PubMed: 8284848]. https://doi.org/10.1016/S0094-0143(21)00587-5 PMid:8284848 |
||||
5. Gillenwater JY, Wein AJ. Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28- 29, 1987. J Urol. 1988;140(1):203-6. [PubMed: 3379688]. https://doi.org/10.1016/S0022-5347(17)41529-1 PMid:3379688 |
||||
6. Hanno PM, Landis JR, Matthews-Cook Y, Kusek J, Nyberg LJ. The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study. J Urol. 1999;161(2):553-7. [PubMed: 9915447]. https://doi.org/10.1016/S0022-5347(01)61948-7 PMid:9915447 |
||||
7. Peeker R, Fall M. Treatment guidelines for classic and non-ulcer interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct. 2000;11(1):23-32. [PubMed: 10738931]. https://doi.org/10.1007/s001920050006 PMid:10738931 |
||||
8. Fall M, Logadottir Y, Peeker R. Interstitial cystitis is bladder pain syndrome with Hunner's lesion. Int J Urol. 2014;21 Suppl 1:79-82. [PubMed: 24807507]. https://doi.org/10.1111/iju.12325 PMid:24807507 |
||||
9. Hand JR. Interstitial cystitis; report of 223 cases (204 women and 19 men). J Urol. 1949;61(2):291-310. [PubMed: 18111850]. https://doi.org/10.1016/S0022-5347(17)69067-0 PMid:18111850 |
||||
10. Chennamsetty A, Ehlert MJ, Peters KM, Killinger KA. Advances in diagnosis and treatment of interstitial cystitis/painful bladder syndrome. Curr Infect Dis Rep. 2015;17(1):454. [PubMed: 25416849]. https://doi.org/10.1007/s11908-014-0454-5 PMid:25416849 |
||||
11. Chelimsky G, Heller E, Buffington CA, Rackley R, Zhang D, Chelimsky T. Co-morbidities of interstitial cystitis. Front Neurosci. 2012;6:114. [PubMed: 22907988]. https://doi.org/10.3389/fnins.2012.00114 PMid:22907988 PMCid:PMC3415690 |
||||
12. Griffiths D, Hofner K, van Mastrigt R, Rollema HJ, Spangberg A, Gleason D. Standardization of terminology of lower urinary tract function: pressure-flow studies of voiding, urethral resistance, and urethral obstruction. International Continence Society Subcommittee on Standardization of Terminology of Pressure-Flow Studies. Neurourol Urodyn. 1997;16(1):1-18. [PubMed: 9021786]. https://doi.org/10.1002/(SICI)1520-6777(1997)16:1<1::AID-NAU1>3.0.CO;2-I |
||||
13. Birder L, Andersson KE. Urothelial signaling. Physiol Rev. 2013;93(2):653-80. [PubMed: 23589830]. https://doi.org/10.1152/physrev.00030.2012 PMid:23589830 PMCid:PMC3768101 |
||||
14. Apodaca G. The uroepithelium: not just a passive barrier. Traffic. 2004;5(3):117-28. [PubMed: 15086788]. https://doi.org/10.1046/j.1600-0854.2003.00156.x PMid:15086788 |
||||
15. Sun TT. Altered phenotype of cultured urothelial and other stratified epithelial cells: implications for wound healing. Am J Physiol Renal Physiol. 2006;291(1):F9-21. [PubMed: 16609152]. 12 Razavi Int J Med. 2017; 5(4):e64551. Federico F https://doi.org/10.1152/ajprenal.00035.2006 PMid:16609152 |
||||
16. Hicks RM. The mammalian urinary bladder: an accommodating organ. Biol Rev Camb Philos Soc. 1975;50(2):215-46. [PubMed: 1100129]. https://doi.org/10.1111/j.1469-185X.1975.tb01057.x PMid:1100129 |
||||
17. Hurst RE, Roy JB, Min KW, Veltri RW, Marley G, Patton K, et al. A deficit of chondroitin sulfate proteoglycans on the bladder uroepithelium in interstitial cystitis. Urology. 1996;48(5):817-21. [PubMed: 8911536]. https://doi.org/10.1016/S0090-4295(96)00322-6 PMid:8911536 |
||||
18. Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology. 2001;57(6 Suppl 1):47-55. [PubMed: 11378050]. https://doi.org/10.1016/S0090-4295(01)01129-3 PMid:11378050 |
||||
19. Kreft ME, Romih R, Kreft M, Jezernik K. Endocytotic activity of bladder superficial urothelial cells is inversely related to their differentiation stage. Differentiation. 2009;77(1):48-59. [PubMed: 19281764]. https://doi.org/10.1016/j.diff.2008.09.011 PMid:19281764 |
||||
20. Cox PJ. Cyclophosphamide cystitis-identification of acrolein as the causative agent. Biochem Pharmacol. 1979;28(13):2045-9. [PubMed: 475846]. https://doi.org/10.1016/0006-2952(79)90222-3 PMid:475846 |
||||
21. Cox PJ, Abel G. Cyclophosphamide cystitis. Studies aimed at its minimization. Biochem Pharmacol. 1979;28(24):3499-502. [PubMed: 231445]. https://doi.org/10.1016/0006-2952(79)90390-3 PMid:231445 |
||||
22. Batista CK, Brito GA, Souza ML, Leitao BT, Cunha FQ, Ribeiro RA. A model of hemorrhagic cystitis induced with acrolein in mice. Braz J Med Biol Res. 2006;39(11):1475-81. [PubMed: 17146560]. https://doi.org/10.1590/S0100-879X2006005000024 PMid:17146560 |
||||
23. Tzan CJ, Berg J, Lewis SA. Effect of protamine sulfate on the permeability properties of the mammalian urinary bladder. J Membr Biol. 1993;133(3):227-42. [PubMed: 8331646]. https://doi.org/10.1007/BF00232022 PMid:8331646 |
||||
24. Lavelle J, Meyers S, Ramage R, Bastacky S, Doty D, Apodaca G, et al. Bladder permeability barrier: recovery from selective injury of surface epithelial cells. Am J Physiol Renal Physiol. 2002;283(2):F242-53. Shimizu I, Kawashima K, Hosoki K. Urodynamics in acetone-induced cystitis of anesthetized rats. Neurourol Urodyn. 1999;18(2):115-27. [PubMed: 10081951]. https://doi.org/10.1152/ajprenal.00307.2001 PMid:12110507 |
||||
25. Keay S, Leitzell S, Ochrzcin A, Clements G, Zhan M, Johnson D. Amouse model for interstitial cystitis/painful bladder syndrome based on APF inhibition of bladder epithelial repair: a pilot study. BMC Urol. 2012;12:17. [PubMed: 22682521]. https://doi.org/10.1186/1471-2490-12-17 PMid:22682521 PMCid:PMC3459789 |
||||
26. Lv YS, Yao YS, Rong L, Lin ME, Deng BH, Xie Y, et al. Intravesical hyaluronidase causes chronic cystitis in a rat model: a potential model of bladder pain syndrome/interstitial cystitis. Int J Urol. 2014;21(6):601-7. [PubMed: 24286489]. https://doi.org/10.1111/iju.12358 PMid:24286489 |
||||
27. Oottamasathien S, Jia W, McCoard L, Slack S, Zhang J, Skardal A, et al. A murine model of inflammatory bladder disease: cathelicidin peptide induced bladder inflammation and treatment with sulfated polysaccharides. J Urol. 2011;186(4 Suppl):1684-92. [PubMed: 21855919]. https://doi.org/10.1016/j.juro.2011.03.099 PMid:21855919 PMCid:PMC3887035 |
||||
28. Elbadawi A. Interstitial cystitis: a critique of current concepts with a new proposal for pathologic diagnosis and pathogenesis. Urology. 1997;49(5A Suppl):14-40. [PubMed: 9145999]. https://doi.org/10.1016/S0090-4295(99)80329-X PMid:9145999 |
||||
29. Galli SJ. New concepts about the mast cell. N Engl J Med. 1993;328(4):257-65. [PubMed: 8418407]. https://doi.org/10.1056/NEJM199301283280408 PMid:8418407 |
||||
30. Bullock AD, Becich MJ, Klutke CG, Ratliff TL. Experimental autoimmune cystitis: a potential murine model for ulcerative interstitial cystitis. J Urol. 1992;148(6):1951-6. [PubMed: 1433651]. https://doi.org/10.1016/S0022-5347(17)37091-X PMid:1433651 |
||||
31. Lin YH, Liu G, Kavran M, Altuntas CZ, Gasbarro G, Tuohy VK, et al. Lower urinary tract phenotype of experimental autoimmune cystitis in mouse: a potential animal model for interstitial cystitis. BJU Int. 2008;102(11):1724-30. [PubMed: 18710451]. https://doi.org/10.1111/j.1464-410X.2008.07891.x PMid:18710451 |
||||
32. Luber-Narod J, Austin-Ritchie T, Banner B, Hollins C3, Maramag C, Price H, et al. Experimental autoimmune cystitis in the Lewis rat: a potential animal model for interstitial cystitis. Urol Res. 1996;24(6):367- 73. [PubMed: 9008331]. https://doi.org/10.1007/BF00389795 PMid:9008331 |
||||
33. Ratliff TL, Klutke CG, Hofmeister M, He F, Russell JH, Becich MJ. Role of the immune response in interstitial cystitis. Clin Immunol Immunopathol. 1995;74(3):209-16. [PubMed: 7859410]. https://doi.org/10.1006/clin.1995.1031 PMid:7859410 |
||||
34. Altuntas CZ, Daneshgari F, Sakalar C, Goksoy E, Gulen MF, Kavran M, et al. Autoimmunity to uroplakin II causes cystitis in mice: a novel model of interstitial cystitis. Eur Urol. 2012;61(1):193-200.. [PubMed: 21719190]. https://doi.org/10.1016/j.eururo.2011.06.028 PMid:21719190 PMCid:PMC3226908 |
||||
35. Lavelle JP, Apodaca G, Meyers SA, Ruiz WG, Zeidel ML. Disruption of guinea pig urinary bladder permeability barrier in noninfectious cystitis. Am J Physiol. 1998;274(1 Pt 2):F205-14. [PubMed: 9458841]. https://doi.org/10.1152/ajprenal.1998.274.1.F205 PMid:9458841 |
||||
36. Ercan F, San T, Cavdar S. The effects of cold-restraint stress on urinary bladder wall compared with interstitial cystitis morphology. Urol Res. 1999;27(6):454-61. [PubMed: 10651134]. https://doi.org/10.1007/s002400050135 PMid:10651134 |
||||
37. Lai H, Gereau R, Luo Y, O'Donnell M, Rudick CN, Pontari M, et al. Animal Models of Urologic Chronic Pelvic Pain Syndromes: Findings From the Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network. Urology. 2015;85(6):1454-65. [PubMed: 26099889]. https://doi.org/10.1016/j.urology.2015.03.007 PMid:26099889 PMCid:PMC4479414 |
||||
38. Cruz F. The future of pharmacologic treatment for bladder pain syndrome/interstitial cystitis: lessons from a meta-analysis. Eur Urol. 2012;61(1):54-5. [PubMed: 21975250] discussion 56-7. https://doi.org/10.1016/j.eururo.2011.09.015 PMid:21975250 |
||||
39. Nazif O, Teichman JM, Gebhart GF. Neural upregulation in interstitial cystitis. Urology. 2007;69(4 Suppl):24-33. [PubMed: 17462476]. https://doi.org/10.1016/j.urology.2006.08.1108 PMid:17462476 |
||||
40. Spanos C, el-Mansoury M, Letourneau R, Minogiannis P, Greenwood J, Siri P, et al. Carbachol-induced bladder mast cell activation: augmentation by estradiol and implications for interstitial cystitis. Urology. 1996;48(5):809-16. [PubMed: 8911535]. https://doi.org/10.1016/S0090-4295(96)00239-7 PMid:8911535 |
||||
41. Jerde TJ, Bjorling DE, Steinberg H, Warner T, Saban R. Determination of mouse bladder inflammatory response to E. coli lipopolysaccharide. Urol Res. 2000;28(4):269-73. [PubMed: 11011967]. https://doi.org/10.1007/s002400000114 PMid:11011967 |
||||
42. Jasmin L, Janni G, Manz HJ, Rabkin SD. Activation of CNS circuits producing a neurogenic cystitis: evidence for centrally induced peripheral inflammation. J Neurosci. 1998;18(23):10016-29. [PubMed: 9822756]. https://doi.org/10.1523/JNEUROSCI.18-23-10016.1998 PMid:9822756 PMCid:PMC6793287 |
||||
43. Rudick CN, Schaeffer AJ, Klumpp DJ. Pharmacologic attenuation of pelvic pain in a murine model of interstitial cystitis. BMC Urol. 2009;9:16. [PubMed: 19909543]. https://doi.org/10.1186/1471-2490-9-16 PMid:19909543 PMCid:PMC2781023 |
||||
44. Pontari MA. Seeking A Rational Approach to the Diagnosis and Treatment of Interstitial Cystitis. Medscape Womens Health. 1996;1(5):2. [PubMed: 9746627]. | ||||
45. Warren JW. Bladder pain syndrome/interstitial cystitis as a functional somatic syndrome. J Psychosom Res. 2014;77(6):510-5. [PubMed: 25455811]. https://doi.org/10.1016/j.jpsychores.2014.10.003 PMid:25455811 |
||||
46. Persu C, Cauni V, Gutue S, Blaj I, Jinga V, Geavlete P. From interstitial cystitis to chronic pelvic pain. J Med Life. 2010;3(2):167-74. [PubMed: 20968203]. | ||||
47. Theoharides TC, Pang X, Letourneau R, Sant GR. Interstitial cystitis: a neuroimmunoendocrine disorder. Ann N Y Acad Sci. 1998;840:619-34. [PubMed: 9629289]. https://doi.org/10.1111/j.1749-6632.1998.tb09601.x PMid:9629289 |
||||
48. Soler R, Bruschini H, Truzzi JC, Martins JR, Camara NO, Alves MT, et al. Urinary glycosaminoglycans excretion and the effect of dimethyl sulfoxide in an experimental model of non-bacterial cystitis. Int Braz J Urol. 2008;34(4):503-11. [PubMed: 18778502] discussion 511. https://doi.org/10.1590/S1677-55382008000400013 PMid:18778502 |
||||
49. Santos NC, Figueira-Coelho J, Martins-Silva J, Saldanha C. Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. Biochem Pharmacol. 2003;65(7):1035-41. [PubMed: 12663039]. https://doi.org/10.1016/S0006-2952(03)00002-9 PMid:12663039 |
||||
50. Smith KJ, Chess-Williams R, McDermott C. Luminal DMSO: effects on detrusor and urothelial/lamina propria function. Biomed Res Int. Razavi Int J Med. 2017 | ||||
5(4):e64551. 13 Federico F 2014;2014:347616. [PubMed: 24949435]. | ||||
51. Tomoe H. In what type of interstitial cystitis/bladder pain syndrome is DMSO intravesical instillation therapy effective? Transl Androl Urol. 2015;4(6):600-4. [PubMed: 26816859]. | ||||
52. Parsons CL, Koziol JA, Proctor JG, Zupkas P, Argade S. Heparin and alkalinized lidocaine versus alkalinized lidocaine for treatment of interstitial cystitis symptoms. Can J Urol. 2015;22(2):7739-44. [PubMed: 25891339]. | ||||
53. Parsons CL, Forrest J, Nickel JC, Evans R, Lloyd LK, Barkin J, et al. Effect of pentosan polysulfate therapy on intravesical potassium sensitivity. Urology. 2002;59(3):329-33. [PubMed: 11880064]. https://doi.org/10.1016/S0090-4295(01)01586-2 PMid:11880064 |
||||
54. Kalota SJ, Stein PC, Parsons CL. Prevention of acrolein-induced bladder injury by pentosanpolysulfate. J Urol. 1992;148(1):163-6. [PubMed: 1377288]. https://doi.org/10.1016/S0022-5347(17)36545-X PMid:1377288 |
||||
55. Chiang G, Patra P, Letourneau R, Jeudy S, Boucher W, Green M, et al. Pentosanpolysulfate inhibits mast cell histamine secretion and intracellular calcium ion levels: an alternative explanation of its beneficial effect in interstitial cystitis. J Urol. 2000;164(6):2119-25. [PubMed: 11061939]. https://doi.org/10.1016/S0022-5347(05)66981-9 PMid:11061939 |
||||
56. Kelly JD, Young MR, Johnston SR, Keane PF. Clinical response to an oral prostaglandin analogue in patients with interstitial cystitis. Eur Urol. 1998;34(1):53-6. [PubMed: 9676414]. https://doi.org/10.1159/000019679 PMid:9676414 |
||||
57. Kuschert GS, Coulin F, Power CA, Proudfoot AE, Hubbard RE, Hoogewerf AJ, et al. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry. 1999;38(39):12959-68. [PubMed: 10504268]. https://doi.org/10.1021/bi990711d PMid:10504268 |
||||
58. Stern R. Hyaluronan catabolism: a new metabolic pathway. Eur J Cell Biol. 2004;83(7):317-25. [PubMed: 15503855]. https://doi.org/10.1078/0171-9335-00392 PMid:15503855 |
||||
59. Sinanoglu O, Dogan Ekici I, Ekici S. Comparison of intravesical application of chondroitin sulphate and colchicine in rat protamine/lipopolysaccharide induced cystitis model. Urol J. 2014;11(1):1296-300. [PubMed: 24595940]. | ||||
60. Eggli PS, Graber W. Cytochemical localization of hyaluronan in rat and human skin mast cell granules. J Invest Dermatol. 1993;100(2):121- 5. [PubMed: 8429234]. https://doi.org/10.1111/1523-1747.ep12462777 PMid:8429234 |
||||
61. Fiander N. Painful bladder syndrome and interstitial cystitis: treatment options. Br J Nurs. 2013;22(9):S26. [PubMed: 23752572] S28-33. | ||||
62. Toole BP. Hyaluronan and its binding proteins, the hyaladherins. Curr Opin Cell Biol. 1990;2(5):839-44. [PubMed: 1707285]. https://doi.org/10.1016/0955-0674(90)90081-O PMid:1707285 |
||||
63. Shao Y, Lu GL, Shen ZJ, He HC. Reduction of intercellular adhesion molecule 1 may play a role in anti-inflammatory effect of hyaluronic acid in a rat model of severe non-bacterial cystitis. World J Urol. 2013;31(3):535-40. [PubMed: 22358112]. https://doi.org/10.1007/s00345-012-0839-8 PMid:22358112 |
||||
64. Arance I, Ramon de Fata F, Angulo JC, Gonzalez-Enguita C, Errando C, Cozar JM, et al. [Available evidence about efficacy of different restoring agents of glycosaminoglycans for intravesical use in interstitial cystitis]. Actas Urol Esp. 2013;37(2):92-9. [PubMed: 23260184]. https://doi.org/10.1016/j.acuroe.2013.05.001 |
||||
65. Negrete HO, Lavelle JP, Berg J, Lewis SA, Zeidel ML. Permeability properties of the intact mammalian bladder epithelium. Am J Physiol. 1996;271(4 Pt 2):F886-94. [PubMed: 8898019]. https://doi.org/10.1152/ajprenal.1996.271.4.F886 PMid:8898019 |
||||
66. Kaufman J, Tyagi V, Anthony M, Chancellor MB, Tyagi P. State of the art in intravesical therapy for lower urinary tract symptoms. Rev Urol. 2010;12(4):e181-9. [PubMed: 21234261]. | ||||
67. Tyagi P, Chancellor M, Yoshimura N, Huang L. Activity of different phospholipids in attenuating hyperactivity in bladder irritation. BJU Int. 2008;101(5):627-32. [PubMed: 18070198]. https://doi.org/10.1111/j.1464-410X.2007.07334.x PMid:18070198 |
||||
68. Nirmal J, Tyagi P, Chancellor MB, Kaufman J, Anthony M, Chancellor DD, et al. Development of potential orphan drug therapy of intravesical liposomal tacrolimus for hemorrhagic cystitis due to increased local drug exposure. J Urol. 2013;189(4):1553-8. [PubMed: 23127767]. https://doi.org/10.1016/j.juro.2012.10.123 PMid:23127767 |
||||
69. Shao Y, Shen ZJ, Rui WB, Zhou WL. Intravesical instillation of hyaluronic acid prolonged the effect of bladder hydrodistention in patients with severe interstitial cystitis. Urology. 2010;75(3):547-50. [PubMed: 20022087]. https://doi.org/10.1016/j.urology.2009.09.078 PMid:20022087 |
||||
70. Lv YS, Zhou HL, Mao HP, Gao R, Wang YD, Xue XY. Intravesical hyaluronic acid and alkalinized lidocaine for the treatment of severe painful bladder syndrome/interstitial cystitis. Int Urogynecol J. 2012;23(12):1715-20. [PubMed: 22576327]. https://doi.org/10.1007/s00192-012-1802-3 PMid:22576327 |
||||
71. Giberti C, Gallo F, Cortese P, Schenone M. Combined intravesical sodium hyaluronate/chondroitin sulfate therapy for interstitial cystitis/bladder pain syndrome: a prospective study. Ther Adv Urol. 2013;5(4):175-9. [PubMed: 23904856]. https://doi.org/10.1177/1756287213490052 PMid:23904856 PMCid:PMC3721440 |
||||
72. Song M, Lim J, Yu HY, Park J, Chun JY, Jeong J, et al. Mesenchymal Stem Cell Therapy Alleviates Interstitial Cystitis by Activating Wnt Signaling Pathway. Stem Cells Dev. 2015;24(14):1648-57. [PubMed: 25745847]. https://doi.org/10.1089/scd.2014.0459 PMid:25745847 PMCid:PMC4499842 |
||||
73. Zhang J, Planey SL, Ceballos C, Stevens SJ, Keay SK, Zacharias DA. Identification of CKAP4/p63 as a major substrate of the palmitoyl acyltransferase DHHC2, a putative tumor suppressor, using a novel proteomics method. Mol Cell Proteomics. 2008;7(7):1378-88. [PubMed: 18296695]. https://doi.org/10.1074/mcp.M800069-MCP200 PMid:18296695 PMCid:PMC2493380 |
||||
74. Yang W, Chung YG, Kim Y, Kim TK, Keay SK, Zhang CO, et al. Quantitative proteomics identifies a beta-catenin network as an element of the signaling response to Frizzled-8 protein-related antiproliferative factor. Mol Cell Proteomics. 2011;10(6):M110 007492. [PubMed: 21422242]. https://doi.org/10.1074/mcp.M110.007492 PMid:21422242 PMCid:PMC3108841 |
||||
75. Shahjee HM, Koch KR, Guo L, Zhang CO, Keay SK. Antiproliferative factor decreases Akt phosphorylation and alters gene expression via CKAP4 in T24 bladder carcinoma cells. J Exp Clin Cancer Res. 2010;29:160.. [PubMed: 21143984]. https://doi.org/10.1186/1756-9966-29-160 PMid:21143984 PMCid:PMC3020166 |
||||
76. Tao YX, Heit M, Lei ZM, Rao CV. The urinary bladder of a woman is a novel site of luteinizing hormone-human chorionic gonadotropin receptor gene expression. Am J Obstet Gynecol. 1998;179(4):1026-31. [PubMed: 9790392]. https://doi.org/10.1016/S0002-9378(98)70222-4 PMid:9790392 |
||||
77. Rao CV. Therapeutic Potential of Human Chorionic Gonadotropin Against Painful Bladder Syndrome/Interstitial Cystitis. Reprod Sci. 2016;23(11):1451-8. [PubMed: 27004802]. https://doi.org/10.1177/1933719116639139 PMid:27004802 |
||||
78. Barthelmes J, Perera G, Hombach J, Dunnhaupt S, Bernkop-Schnurch A. Development of a mucoadhesive nanoparticulate drug delivery system for a targeted drug release in the bladder. Int J Pharm. 2011;416(1):339-45. [PubMed: 21726619] https://doi.org/10.1016/j.ijpharm.2011.06.033 PMid:21726619 |